Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Cell cultures "poor surrogates" for disease
Petri dish
Lab-grown cells used in studies of human disease may not act as a faithful mimic of real tissue.

Studies of human disease rely on the use of cell cultures

Researchers at the University of Edinburgh have discovered that cell cultures, used in biology and medical research, may not act as a faithful mimic of real tissue.

The findings could affect the interpretation of past studies and provide important clues for improving cell cultures in the future.

Studies of human disease, including cancer, rely on the use of cell cultures that have often been grown for decades.

However, research led by the MRC Human Genetics Unit at the University of Edinburgh found that cells change within one week of growth in a laboratory dish.

The analysis provides new insight into how faithfully these cells mimic real tissue, and how models of human disease can still be improved.

Study author Richard Meehan from the MRC Human Genetics Unit at the University of Edinburgh, UK, said: “We were astonished by the speed and spread of the changes. Many cultured cells used in research have been grown for decades and as a result are likely to have very different properties from the cells they are supposed to model.  

"Our findings suggest that we have to be circumspect about the interpretation of some previous experiments, and our data reinforces a growing realisation that cell line models of human diseases, particularly cancer, can be poor surrogates for many aspects of in-vivo biology.”

The study, Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems, is published in Genome Biology.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.